Synthesis and structure-activity relationships of N-methyl-5,6,7- trimethoxylindoles as novel antimitotic and vascular disrupting agents

Journal of Medicinal Chemistry

Volumn 56, Issue 4, 2013, Pages 1467-1477

  Zhao, Deng Gao ^a   Chen, Jianjun ^a   Du, Ya Rong ^a   Ma, Yan Yan ^a   Chen, Ya Xiong ^b   Gao, Kun ^a   Hu, Bu Rong ^b  

^a LANZHOU UNIVERSITY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

(1 ACETYL 5,6,7 TRIMETHOXY 1H INDOL 3 YL)(4 METHOXYPHENYL)METHANONE; (1 BENZENESULFONYL 5,6,7 TRIMETHOXY 1H INDOL 3 YL)(4 METHOXYPHENYL)METHANONE; (3 (BENZYLOXY) 4 METHOXYPHENYL) (5,6,7 TRIMETHOXY 1 METHYL 1H INDOL 3 YL)METHANONE; (3 (BENZYLOXY) 4 METHOXYPHENYL) (5,6,7 TRIMETHOXY 1H INDOL 3 YL)METHANONE; (3 CHLORO 4 METHOXYPHENYL) (5,6,7 TRIMETHOXY 1H INDOL 3 YL)METHANONE; (3 FLUORO 4 METHOXYPHENYL) (5,6,7 TRIMETHOXY 1 METHYL 1H INDOL 3 YL)METHANONE; (3 FLUORO 4 METHOXYPHENYL) (5,6,7 TRIMETHOXY 1H INDOL 3 YL)METHANONE; (3 HYDROXY 4 METHOXYPHENYL) (5,6,7 TRIMETHOXY 1 METHYL 1H INDOL 3 YL)METHANONE; (3 HYDROXY 4 METHOXYPHENYL) (5,6,7 TRIMETHOXY 1,2 DIMETHYL 1H INDOLE 3 YL)METHANONE; (3 HYDROXY 4 METHOXYPHENYL) (5,6,7 TRIMETHOXY 1H INDOL 1 YL)METHANONE; (3 HYDROXY 4 METHOXYPHENYL) (5,6,7 TRIMETHOXY 1H INDOL 3 YL)METHANONE; (3 HYDROXY 4 METHOXYPHENYL) (5,6,7 TRIMETHOXY 2 METHYL 1H INDOL 3 YL)METHANONE; (5,6,7 TRIMETHOXY 1 METHYL 1H INDOL 3 YL)(4 METHOXYPHENYL)METHANONE; (5,6,7 TRIMETHOXY 1H INDOL 1 YL)(4 METHOXYPHENYL)METHANONE; (5,6,7 TRIMETHOXY 1H INDOL 3 YL)(2 METHOXYPHENYL)METHANONE; (5,6,7 TRIMETHOXY 1H INDOL 3 YL)(3 METHOXYPHENYL)METHANONE; (5,6,7 TRIMETHOXY 1H INDOL 3 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (5,6,7 TRIMETHOXY 1H INDOL 3 YL)(4 METHOXYPHENYL)METHANONE; 1 (4 METHOXYBENZYL) 5,6,7 TRIMETHOXY 1H INDOLE; 2 METHOXY 5 ((5,6,7 TRIMETHOXY 1H INDOL 3 YL)METHYL)PHENOL; 2 METHOXY 5 (5,6,7 TRIMETHOXY 1H INDOL 1 YL)METHYL)PHENOL; 3 (3 FLUORO 4 METHOXYBENZYL) 5,6,7 TRIMETHOXY 1H INDOLE; 3 (3,4,5 TRIMETHOXYBENZYL) 5,6,7 TRIMETHOXY 1H INDOLE; 3 (4 METHOXYBENZYL) 5,6,7 TRIMETHOXY 1H INDOLE; ANTIMITOTIC AGENT; COLCHICINE; COMBRETASTATIN A4; INDOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE ASSEMBLY; POLYMERIZATION; STRUCTURE ACTIVITY RELATION; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84874605974     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3014663     Document Type: Article

References (32)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease Nature Med. 1995, 1, 27-31
2. Siemann, D. W.; Chaplin, D. J.; Horsman, M. R. Vascular targeted therapies for treatment of malignant disease Cancer 2004, 100, 2491-2499 (Pubitemid 38715753)
3. Tozer, G. M.; Kanthou, C.; Baguley, B. C. Disrupting tumour blood vessels Nature. Rev. Cancer 2005, 5, 423-435 (Pubitemid 40791485)
4. Thorpe, P. E.; Chaplin, D. J.; Blakey, D. C. The First International Conference on Vascular Targeting: meeting overview Cancer Res. 2003, 63, 1144-1147 (Pubitemid 36278450)
5. Baguley, B. C.; Holdaway, K. M.; Thomsen, L. L.; Zhuang, L.; Zwi, L. J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism Eur. J. Cancer 1991, 27, 482-487
6. Hill, S. A.; Lonergan, S. J.; Denekamp, J.; Chaplin, D. J. Vinca alkaloids: anti-vascular effects in a murine tumour Eur. J. Cancer 1993, 29A, 1320-1324 (Pubitemid 23169906)
7. Chaplin, D. J.; Pettit, G. R.; Parkins, C. S.; Hill, S. A. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents Br. J. Cancer 1996, 74 (Suppl) 86-88
8. Dark, G. G.; Hill, S. A.; Prise, V. E.; Tozer, G. M.; Pettit, G. R.; Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature Cancer Res. 1997, 1829-1834 (Pubitemid 27209705)
9. Hill, S. A.; Tozer, G. M.; Chaplin, D. J. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503 Anticancer Res. 2002, 22, 1453-1458 (Pubitemid 34839149)
10. Davis, P. D.; Dougherty, G. J.; Blakey, D. C.; Galbraith, S. M.; Tozer, G. M.; Holder, A. L.; Naylor, M. A.; Nolan, J.; Stratford, M. R. L.; Chaplin, D. J.; Hill, S. A. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature Cancer Res. 2002, 62, 7427-7253
11. Flynn, B. L.; Gill, G. S.; Grobelny, D. W.; Chaplin, J. H.; Paul, D.; Lesker, A. F.; Lavranos, T. C.; Chalmers, D. K.; Charman, S. A.; Kostewicz, E.; Shackleford, D. M.; Morizzi, J.; Hamel, E.; Jung, M. K.; Kremmidiotis, G. Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[ b ]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties J. Med. Chem. 2011, 54, 6014-6027
12. Schwartz, E. L. Antivascular Actions of Microtubule-Binding Drugs Clin. Cancer Res. 2009, 15, 2594-2601
13. Kremmidiotis, G.; Leske, A. F.; Lavranos, T. C.; Beaumont, D.; Gasic, J.; Hall, A.; O'Callaghan, M.; Matthews, C. A.; Flynn, B. L. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy Mol. Cancer Ther. 2010, 9, 1562-1573
14. Bussolati, B.; Deambrosis, I.; Russo, S.; Deregibus, M. C.; Camussi, G. Altered angiogenesis and survival in human tumor-derived endothelial cells FASEB J. 2003, 17, 1159-116
15. Watts, M. E.; Woodcock, M.; Arnold, S.; Chaplin, D. J. Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumour secreted factors Anticancer Res. 1997, 17, 71-75 (Pubitemid 27116647)
16. Li, Q.; Sham, H. L. Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer Expert Opin. Ther. Pat. 2002, 12, 1663-1702 (Pubitemid 35355903)
17. Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle Med. Res. Rev. 1998, 18, 259-296 (Pubitemid 28346389)
18. Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal chemistry of combretastatin A4: present and future directions J. Med. Chem. 2006, 49, 3033-3044 (Pubitemid 43830499)
19. Hsieh, H. P.; Liou, J. P.; Mahindroo, N. Pharmaceutical Design of Antimitotic Agents Based on Combretastatins Curr. Pharm. Des. 2005, 11, 1655-1677 (Pubitemid 40668143)
20. Nam, N. Combretastatin A-4 Analogues as Antimitotic Antitumor Agents Curr. Med. Chem. 2003, 10, 1697-1722 (Pubitemid 37038595)
21. Arthuis, M.; Pontikis, R.; Chabot, G.; Quentin, L.; Scherman, D.; Florent, J. C. Domino approach to 2-aroyltrimethoxyindoles as novel heterocyclic combretastatin A4 analogues Eur. J. Med. Chem. 2011, 46, 95-100
22. Lai, M. J.; Kuo, C. C.; Yeh, T. K.; Hsieh, H.-P; Chen, L. T.; Pan, W.-Y.; Hsu, K.-Y.; Chang, J. Y.; Liou, J. P. Synthesis and Structure-Activity Relationships of 1-Benzyl-4,5,6-trimethoxyindoles as a Novel Class of Potent Antimitotic Agents ChemMedChem 2009, 4, 588-593
23. Lee, H. Y.; Chang, J. Y.; Chang, L. Y.; Lai, W. Y.; Lai, M. J.; Shih, K. H.; Kuo, C. C.; Chang, C. C.; Liou, J. P. Concise syntheses of N -aryl-5,6,7-trimethoxyindoles as antimitotic and vascular disrupting agents: application of the copper-mediated Ullmann-type arylation Org. Biomol. Chem. 2011, 9, 3154-3157
24. Morin, R.; Benington, F.; Clark, L. Synthsesis of 5,6,7-trimethoxyindole possible intermediary metabolite of mescaline J. Org. Chem. 1957, 22, 331-332
25. Yang, C. X.; Patel, H. H.; Ku, Y. Y.; Shah, R.; Sawick, D. The use of Lewis acid in the reaction of zinc salts of indoles and acyl chloride Synth. Commun. 1997, 27, 2125-2132 (Pubitemid 27224062)
26. Liou, J. P.; Chang, Y. L.; Kuo, F. M.; Chang, C. W.; Tseng, H. Y.; Wang, C. C.; Yang, Y. N.; Chang, J. Y.; Lee, S. J.; Hsieh, H. P. Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles, and 3-aroylindoles, as novel classes of potent antitubulin agents J. Med. Chem. 2004, 47, 4247-4257
27. Liou, J. P.; Mahindroo, N.; Chang, C. W.; Guo, F. M.; Lee, S. W.; Tan, U. K.; Yeh, T. K.; Kuo, C. C.; Chang, Y. W.; Lu, P. H.; Tung, Y. S.; Lin, K. T.; Chang, J. Y.; Hsieh, H. P. Structure-activity relationship studies of 3-aroylindoles as potent antimitotic agents ChemMedChem 2006, 1, 1106-1118 (Pubitemid 44622251)
28. Hofmann, M.; Hampel, M.; Kanzian, T.; Mayr, H. Electrophilic alkylations in neutral aqueous or alcoholic solutions Angew. Chem., Int. Ed. 2004, 43, 5402-5405 (Pubitemid 39433933)
29. Kruczynski, A.; Poli, M.; Chazottes, R.; Berrichon, G.; Ricome, C.; Giavazzi, R.; Hill, B.; Taraboletti, G. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development Eur. J. Cancer 2006, 42, 2821-2832 (Pubitemid 44584664)
30. Minotti, A. M.; Barlow, S. B.; Cabral, F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin J. Biol. Chem. 1991, 266, 3987-3994 (Pubitemid 21909306)
31. Theeramunkong, S.; Caldarelli, A.; Massarotti, A.; Aprile, S.; Caprioglio, D.; Zaninetti, R.; Teruggi, A.; Pirali, P.; Grosa, G.; Tron, G. C.; Genazzani, A. A. Dipartime regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues J. Med. Chem. 2011, 54, 4977-4986
32. Deng, Z.-T.; Peng, T.; Wang, P.; Qi, X.; Chen, X.-H.; Li, Y.-X.; Song, C.-L.; Geng, M.-Y.; Li, J. Effects of the novel vascular targeting agent MDS-11P on tumor vascularity and its antitumor activity Biochem. Pharmacol. 2011, 82, 1832-1842